Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on December 8, 2004
J Am Soc Nephrol 16: 555-563, 2005
© 2005 American Society of Nephrology
doi: 10.1681/ASN.2004050380
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2004050380v1
16/2/555    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dragon-Durey, M.-A.
Right arrow Articles by Frémeaux-Bacchi, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dragon-Durey, M.-A.
Right arrow Articles by Frémeaux-Bacchi, V.
Related Collections
Right arrowRelated Article

Clinical Immunology and Pathology

Anti–Factor H Autoantibodies Associated with Atypical Hemolytic Uremic Syndrome

Marie-Agnès Dragon-Durey*, Chantal Loirat{dagger}, Sylvie Cloarec{ddagger}, Marie-Alice Macher{dagger}, Jacques Blouin*, Hubert Nivet{ddagger}, Laurence Weiss§, Wolf Herman Fridman*,|| and Véronique Frémeaux-Bacchi*,||

* Service d’Immunologie Biologique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris; {dagger} Service de Néphrologie, Hôpital Robert Debré, Assistance Publique-Hôpitaux de Paris, Paris; {ddagger} Unité de Néphrologie Pédiatrique, Centre Hospitalier de Tours, Tours; § Service d’Immunologie Clinique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris; and || INSERM U255, Institut des Cordeliers, Paris, France

Address correspondence to: Dr. Marie-Agnès Dragon-Durey, Service d’Immunologie Biologique, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75 015 Paris, France. Phone: 33-1-56-09-39-41; Fax: 33-1-56-09-20-80; E-mail: marie-agnes.durey{at}egp.ap-hop-paris.fr


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Several studies have demonstrated genetic predisposition in non–shigatoxin-associated hemolytic uremic syndrome (HUS), involving regulatory proteins of the complement alternative pathway: Factor H (FH) and membrane co-factor protein (CD46). Regarding the observations of thrombotic thrombocytopenic purpura patients, in whom a von Willebrand factor protease (ADAMST-13) deficiency may be inherited or acquired secondary to IgG antibodies, it was speculated that HUS might occur in a context of an autoimmune disease with the development of anti-FH antibodies leading to an acquired FH deficiency. The presence of FH autoantibodies was investigated by an ELISA method using coated purified human FH in a series of 48 children who presented with atypical HUS and were recruited from French university hospitals. Anti-FH IgG antibodies were detected in the plasma of three children who presented with recurrent HUS. The anti-FH specificity was conserved by the Fab'2 fraction. The plasma FH activity was found to be decreased, whereas plasma FH antigenic levels and FH gene analysis were normal, indicating that the presence of anti-FH antibodies led to an acquired functional FH deficiency. This report supports for the first time that HUS may occur in a context of an autoimmune disease with the development of anti-FH–specific antibody leading to an acquired FH deficiency. This new mechanism of functional FH deficiency may lead to the design of new approaches of diagnosis and treatment with a particular interest in plasma exchanges or immunosuppressive therapies.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Thrombotic microangiopathy (TMA) disorders include thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) (1). The common clinical features of TMA associate microangiopathic hemolytic anemia, thrombocytopenia, and variable organ damage. Classically, HUS is characterized by an acute renal failure, whereas in TTP, neurologic symptoms are predominant. Typical HUS occurs in infants and young children, in relation to shigatoxin (Stx) produced by some strains of bacteria such as 0157/H7 Escherichia coli and has a good outcome. In contrast, atypical HUS occurs at any age, including newborn, and has a frequently recurrent course and a poor renal prognosis. Several studies have demonstrated genetic predisposition in atypical HUS, in both familial and sporadic cases, involving two regulatory proteins of the complement alternative pathway: Factor H (FH) and membrane co-factor protein (MCP; or CD46). The human complement system can be activated through three different pathways: The classical and lectin pathways and the alternative pathway that converge to generate either classical or alternative C3-convertase enzymes. C3 convertase enzymes’ function is the proteolytic activation of the third component of complement C3 to C3a and C3b, leading to covalent attachment of C3b to surfaces during complement activation. FH and MCP serve as co-factors for the C3b-inactivating enzyme complement factor I. FH also inhibits the formation and accelerates the decay of the alternative C3-convertase. FH is a single-chain serum glycoprotein of 150 kD with modular structure consisting of a tandem array of 20 homologous units (2), called short consensus repeats (SCR) or complement control protein, composed of approximately 60 amino acid residues each (3). Homozygous or heterozygous FH deficiencies (reviewed in 4) as well as single amino acid exchanges within the C-terminal domains of the protein have been reported to be associated with atypical forms of HUS (5–9). Richards et al. (10) and Noris et al. (11) found mutations in the CD46 gene in four affected families. However, >50% of cases, including HUS patients with decreased plasma C3 concentrations, remain without identified etiologic factor. Regarding these observations, we speculate that HUS might occur in a context of an autoimmune disease as described in patients with TTP, in whom a von Willebrand factor protease (ADAMST-13) deficiency may be inherited or acquired secondary to IgG antibodies (12–16). We investigated for the presence of FH autoantibodies in a series of 48 children who presented with atypical HUS. We report for the first time on three children who developed anti-FH autoantibodies in a context of atypical HUS.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Patients
Forty-eight children who presented with atypical (non–Stx-related) HUS were recruited from the departments of pediatric nephrology of French University hospitals from 1997 to 2003. EDTA plasma samples were obtained from patients and stored at –70°C. Informed consent of parents of children was obtained before DNA analysis.

Complement Assays
Measurement of CH50 activity in EDTA plasma samples was performed as described previously (17). Plasma concentrations of the complement components C4, C3, and factor B (FB) antigens were measured by nephelometry (Dade Behring, Paris La Defense, France). FH antigen concentrations were measured by sensitive ELISA methods as described previously (4).

FH activity was measured by assessing the ability of test plasma to dissociate a preformed cell-bound C3bBb convertase, as described previously (18). Results were expressed as the percentage of values obtained in the same experiment with a reference plasma pool prepared from 100 healthy blood donors (normal ranges were 100 ± 30% as calculated with the results from 50 individual healthy donors).

Genomic FH DNA Sequencing
For genomic FH DNA analysis, genomic DNA was extracted from whole blood using the proteinase K/phenol method (19). Uncloned genomic DNA was amplified by means of a PCR using oligonucleotides flanking each exon. Primer sequences, length of the PCR-amplified fragments, and temperatures of hybridization used for each reaction and direct DNA sequencing procedure have been previously described (4). Sequence analyses were performed using the Sequencher software.

Anti-FH Antibody Assessment
Presence of anti-FH antibody was detected by using an ELISA method. Nunc MaxiSorp ELISA plates (Nunc, Roskilde, Denmark) were coated with 0.3 µg of purified human FH (Calbiochem, Meudon, France). After washing and blocking free reactive sites with PBS that contained 1% BSA, the plasma to be tested was added at a dilution of 1:50 for 1 h at room temperature. After washing, the plates were incubated for 1 h at room temperature with a goat anti-human IgG antibody, specific for the {gamma} chain, labeled with horseradish peroxidase (Sigma-Aldrich, Steinheim, Germany). After additional washing, enzymatic activity was revealed using the orthophenyldiamine substrate. Optical density above the mean + 2 SD of those obtained in 50 individual healthy donors’ plasma was considered as positive.

Positive samples were subsequently tested at serial dilutions, and a titer was determined. Antibody titers were expressed as arbitrary units per ml (AU/ml) calculated as (S – B) x 1000/(P –B), where S is optical density of the test sample diluted at 1/200, B is absorbency of the blank, and P is absorbency of the reference positive plasma diluted (1:200) given an arbitrary titer of 1000 AU/ml.

The isotype of the IgG anti-FH antibodies was determined by the use of mouse monoclonal anti-IgG1, IgG2, and IgG3 antibody at the second step of the ELISA method. After additional washing, plates were incubated with an anti-mouse IgG labeled with horseradish peroxidase (Sanofi Pasteur, Marne-la-Coquette, France) and further incubated for 1 h at room temperature. Enzymatic activity was revealed using the orthophenyldiamine substrate.

Purification of IgG and Fab'2 Preparation
Total IgG was purified from plasma of two positive patients (patients 1 and 2) on protein G Sepharose followed by acid elution. The eluted IgG-containing fractions were then dialyzed against PBS. The purity of IgG preparations was assessed by SDS-PAGE under reducing and nonreducing conditions.

For Fab'2 preparation, the purified IgG were dialyzed against sodium acetate (CH3COONa) 0.1 M (pH = 4.1) at room temperature during 90 min. Twenty micrograms of Pepsine (3045 units/mg protein; Sigma-Aldrich) were added for 1 mg of IgG and incubated during 18 h at 37°C. Enzymatic reaction was stopped by adjusting pH to 7 with a TRIS 2 M solution. The Fab'2 preparations were then dialyzed against PBS. The purity of Fab'2 preparations was assessed by SDS-PAGE under reducing and nonreducing conditions.

FH Binding Inhibiting Assays
Inhibition of the IgG binding to immobilized FH by fluid-phase FH was performed. Diluted (1:500) plasma was preincubated with increasing amounts (0 to 10 µg) of purified FH (Calbiochem, Meudon, France) during 18 h at 4°C and then directly tested in an FH-coated microtiter plate, and ELISA was performed as described previously. Positive plasma was also tested by ELISA with co-incubation of serial dilutions of sheep polyclonal anti-human FH (The Binding Site, Birmingham, UK) or mouse anti-human FH monoclonal antibody (Serotec, Fidlington, UK).

Surface-Bound C3b-Binding Assay
The binding of FH to surface-bound C3b was determined using an ELISA method. Briefly, Nunc MaxiSorp ELISA plates were coated with 62.5 ng of purified C3b overnight at 4°C. After washing and blocking free reactive sites with PBS that contained 1% BSA, biotinylated purified FH at various concentrations was added for 1 h at room temperature alone or after preincubation with various concentrations of patient 1 or 2 purified IgG overnight at 4°C. After washing, the plates were incubated with a 1:1000 dilution of streptavidin biotinylated horseradish peroxidase for 30 min at room temperature. After additional washing, immobilized FH was revealed using the orthophenyldiamine substrate.

Fluid-Phase C3b Co-factor Activity Assay
The fluid-phase co-factor activity of FH was determined in a C3b proteolytic assay using purified proteins. In brief, 3 µg of biotinylated C3b was added to 1 µg of factor I (Sigma Aldrich), 1 µg of FH, and various amounts of purified IgG and was incubated at 37°C for 1 h in veronal buffered saline (pH 7.4). Proteolysis of C3b was evaluated by analyzing the cleavage of the {alpha} chain of C3b and the generation of the {alpha}43/45-kD fragments using 8% SDS-PAGE under reducing conditions. Western blot analysis was performed on nitrocellulose membranes by using streptavidin biotinylated horseradish peroxidase and 4-chloro-1-napthol and 1% hydrogen peroxide as substrates.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Case Reports
Among the 48 children tested, three children exhibited a positive ELISA anti-FH assay. Clinical features are summarized in Table 1.


View this table:
[in this window]
[in a new window]

  		Table 1. Main clinical and biological features of the three children with anti-FH antibodiesa

 
Patient 1.
A 10-yr-old girl was referred because of fever, headache, vomiting, and bloody diarrhea. On examination, the girl presented with jaundice, edema, oligo-anuria, and high BP. Routine laboratory tests showed pronounced hemolytic anemia (hemoglobin, 5.1 g/dl) with 13% schizocytes on peripheral blood smears, thrombocythemia (platelets, 51 x 109/L), and renal failure (serum creatinine, 1218 µmol/L). Urine output normalized after 24 d, and serum creatinine decreased to 260 µmol/L. PCR of Stx in the stools and detection of serum antibodies against LPS (026, 091, 0103, 0111, 0128, 0145, and 0157) were negative. Biologic exploration revealed no causative factor (Table 1) but showed the presence of antinuclear antibodies (ANA; titers 1:320) with a speckled pattern without anti–extractable nuclear antigens (anti-ENA) antibody identified and no anti–double-stranded DNA (dsDNA) antibody. Immunologic evaluation did not detect any other autoantibody. The evolution was marked by two recurrences of HUS over 1 mo, with involvement of extrarenal organs including cytolytic hepatitis, pancreatitis, pericarditis, and septic complications. The child was in ESRD after 2 mo despite a therapy associating antihypertensive treatment, transfusions, two fresh frozen plasma (FFP) infusions during the first relapse, and one intravenous IgG infusion (500 mg/kg) during the second relapse. Uncontrolled hypertension led to a bilateral nephrectomy 6 mo later. Histology of the nephrectomy specimen showed severe glomerular and arterial microangiopathy without deposits on immunohistochemistry staining.

Patient 2.
A 3-yr-old boy was hospitalized because of anemia after an episode of diarrhea 15 d before. Biologic evaluation showed pronounced anemia (hemoglobin, 5.6 g/dl) with mild thrombocytopenia (platelets, 93 x 109/L) and renal involvement (serum creatinine, 113 µmol/L). PCR of Stx in the stools and detection of serum antibodies against LPS (seven serotypes tested including 0157:H7) were negative. He received one blood transfusion. Ten days later, he developed oliguric renal failure with hypertension and recurrence of anemia and thrombocytopenia that required blood transfusion, hemodialysis, and five plasma exchanges in 10 d. Renal biopsy showed mild glomerular and arterial microangiopathy. A recurrence 2 mo later was treated with seven plasma exchanges with FFP replacement in 21 d, which were progressively spaced out to one session every 3 wk during 4 mo. A second recurrence occurred 1 mo after, again requiring plasma exchanges during 6 mo. Four months after the last plasma exchange was a third recurrence, and plasma exchange treatment was introduced again associated with glucocorticoids at 1.4 mg/kg per d with progressive decrease. Biologic exploration revealed no causative factor (Table 1) but showed low titers (1:100) of ANA with a speckled pattern without ENA antibody and anti-dsDNA antibody. Immunologic evaluation did not detect any other autoantibody. Presently, 28 mo after the onset, the child remains on plasma exchange therapy once every 3 wk associated with 1.5 mg/kg per d azathioprine and antihypertensive treatment. Renal function remains normal.

Patient 3.
A 9-yr-old boy was referred because of asthenia, pallor, vomiting, and abdominal pain without diarrhea. Biologic evaluation showed hemolytic anemia (hemoglobin, 7.1 g/dl, 3% schizocytes) with major thrombocytopenia (platelets, 19 x 109/L) and renal failure (serum creatinine, 236 µmol/L). PCR of Stx in the stools and detection of serum antibodies against LPS (seven serotypes tested, including 0157:H7) were negative. He received blood transfusion. Twelve days later, he developed a relapse that was treated with plasma exchanges with FFP replacement, which were continued once a week during 9 mo because of two recurrences. A treatment with glucocorticoids was introduced at month 5 with very progressive decrease. Biologic exploration revealed no causative factor (Table 1) but showed low titers (1:200) of ANA with a speckled pattern without ENA antibody and anti-dsDNA antibody. Immunologic evaluation did not detect any other autoantibody, but antiplatelets antibodies were developed during the follow-up. Presently, 31 mo after the onset, he needs antihypertensive treatment with low doses of glucocorticoids and has normal renal function.

Complement Components Assessment
Plasma complement profiles of the three patients are depicted in Table 2. Patient 1 was investigated at the acute phase of the disease, and she exhibited complement consumption through the alternative pathway, as indicated by low plasma levels of the complement alternative pathway components C3 and factor B (FB). FH antigenic level was normal, whereas FH activity was profoundly decreased (10%). A few weeks later and during the 18 mo of follow-up, the child exhibited persistent low FH activity with normal FH antigenic level and decreased C3 and FB plasma levels. Complement components of patient 2 were investigated 2 mo after the onset of the disease and exhibited normal immunochemical levels that remained stable subsequently. Functional FH activity could not be investigated at the acute phase and was marginally decreased (70% of normal) when studied at 27 mo of follow-up. Patient 3 was investigated 3 mo after onset. Complement components exploration showed low C3 and normal antigenic FH levels at 3, 24, and 29 mo of follow-up. Functional FH activity was decreased at 56 and 67% of normal when studied at 24 and 29 mo, respectively. In the three patients, all exons of FH gene were analyzed by sequencing, and no abnormality was found.


View this table:
[in this window]
[in a new window]

  		Table 2. Results of complement investigation of the three patients at different selected timesa

 
Anti-FH Antibody
An antibody of IgG isotype reactive with FH was found in the plasma of the three patients by ELISA. The isotypes were subsequently identified as IgG3 in patient 1, IgG1 in patient 2, and IgG1 and 3 in patient 3 (Figure 1). The IgG fractions and the derived Fab'2 conserved the anti-FH specificity, whereas the plasma IgG depletion removed the anti-FH reactivity (Figure 2).



View larger version (10K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 1. Isotype determination of the anti–factor H (anti-FH) antibodies of the three patients. The anti-FH binding was determined using 1:50 diluted plasma samples and anti-human IgG ({blacksquare}), IgG1 ({square}) and IgG3 ( {U2593}) antibodies. Anti-FH IgG were identified as IgG3 in patient 1, IgG1 in patient 2, and IgG1 and 3 in patient 3.

 


View larger version (12K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 2. Anti-FH specificity of purified IgG and derived Fab'2 from patients’ plasma. The plasma IgG ({blacksquare}), purified IgG ({blacktriangleup}), and derived Fab'2 (x) exhibited the anti-FH specificity, whereas plasma IgG depletion ({diamondsuit}) removed the anti-FH reactivity.

 
Plasma IgG binding on immobilized FH was found to be inhibited by incubation with purified FH and with sheep polyclonal anti-human FH, whereas the binding was not inhibited by a mouse monoclonal anti-FH antibody specific for a region that comprised SCR1 to 4, by neither nonspecific sheep polyclonal nor mouse monoclonal antibodies (Figure 3).



View larger version (19K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 3. Inhibition of FH IgG binding by purified FH and sheep polyclonal anti-human FH antibody. Diluted plasma (1:500) of the three patients was submitted to the ELISA anti-FH assay, alone (lane 1) or with co-incubation with 1 µg of purified FH (lane 2), polyclonal (lane 3) or monoclonal (lane 4) anti-FH antibodies, or nonspecific sheep polyclonal (lane 5) and nonspecific mouse monoclonal (lane 6) antibodies diluted at the same concentration.

 
The 45 other children who presented with atypical HUS were negative for the test. We tested control samples, including samples from children who presented with typical HUS (n = 10) and patients who exhibited anti-DNA (n = 10) anti-cardiolipin (n = 10), antineutrophil cytoplasmic (n = 10), antiglomerular basement membrane (n = 10) or anti-alternative C3 convertase (n = 10) antibodies. None of them was found to be positive (Figure 4).



View larger version (11K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 4. Results of the anti-FH ELISA assay in patients who presented with anti-DNA antibodies (n = 10), anti-cardiolipin antibodies (n = 10), anti–glomerular basement membrane antibodies (n = 10), antineutrophil cytoplasmic antibodies (ANCA; n = 10), anti-alternative C3 convertase (C3Nef; n = 10) antibodies, and Stx-related hemolytic uremic syndrome (HUS; n = 10) or atypical HUS (n = 48).

 
Anti-FH arbitrary units were defined using a reference positive sample. For patient 1, titers were high at the two first samples and decreased and then remained stable during the 19 mo of follow-up. After immunosuppressive treatment, anti-FH antibody titers decreased, and concomitantly FH activity was found to rise to 80% of normal value. For patient 2 (Figure 5), titers were found to be higher at month 15 (2 mo after last plasma exchange and 2 mo before the third relapse) than at month 3 and mildly decreased at month 23 during plasma exchange therapy. At 30 mo of follow-up, plasma samples that were obtained before and after plasma exchange treatment were tested. The results showed a rise of functional FH activity from 68 to 140% of normal after plasma exchange. Concomitantly, anti-FH antibody titers were found to be significantly decreased when tested immediately after plasma exchange treatment at month 30 (Figure 5). Patient 3 exhibited stable titers of anti-FH IgG at months 3 and 24.



View larger version (11K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 5. Evolution of the patient 2’s anti-FH antibody titers during the progress of the disease. The plasma exchange therapy periods are indicated by double arrows. At month 30, samples were obtained immediately before and after plasma exchange, and FH function and anti-FH antibody titers were evaluated.

 
In Vitro FH Functional Activity Assays
The binding of various concentrations of biotinylated purified FH to surface-bound C3b was tested in the presence of patient 1 and 2 plasma-purified IgG. We observed a binding of increasing amounts of biotinylated FH to surface-bound C3b that was not disturbed by the IgG-containing anti-FH antibodies (Figure 6).



View larger version (12K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 6. Biotinylated FH binding to surface-bound C3b in the presence of 500 ng of purified patient 1 ({blacksquare}), patient 2 ({blacktriangleup}), or control nonspecific ({diamondsuit}) IgG.

 
The co-factor activity of FH in the proteolysis of fluid-phase C3b by factor I was tested in presence of patient 1 and 2 plasma-purified IgG. This activity was similar to the activity of purified FH alone (data not shown).


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
We report for the first time on the presence of persistent anti-FH autoantibodies in a context of atypical HUS. Our results indicate that the anti-FH specificity is IgG dependent and is conserved by the Fab'2 fraction. Plasma IgG binding on FH was inhibited by a polyclonal anti-FH antibody but not by a mouse monoclonal anti-FH antibody specific for a region that comprised SCR1 to 4, showing evidence that the implicated epitopes are not localized in the N terminal domain of the FH protein. A monoclonal Ig {lambda} light-chain dimer causing uncontrolled alternative pathway activation by binding to the SCR3 of FH was isolated previously from the serum of a patient with hypocomplementemic membranoproliferative glomerulonephritis (20). It is interesting that both atypical HUS and membranoproliferative glomerulonephritis have already been reported to be associated with homozygous FH deficiency (4,21).

No anti-FH antibody was found in a large series of plasma samples, including healthy control subjects or patients of various autoimmune disorders, suggesting that these antibodies are specific to particular forms of atypical HUS. These antibodies were found in three of 48 children who presented with non Stx-related HUS. Thus, the anti-FH antibody prevalence is approximately 6% in this study population as detected by our experimental conditions. The frequency of anti-FH antibody may be underestimated by the use of plastic-coated FH, which might hide some epitope of the protein and thus impair the detection of fluid-phase anti-FH antibody.

We chose to measure the FH activity by reference hemolytic test because this method allows the investigation of both the C3b binding capacity of FH and its activity of decay-dissociation of Bb from the preformed cell-bound nickel-stabilized C3 convertase (18). In our patients, plasma FH activity was found to be decreased, whereas plasma FH antigenic levels were normal and the FH gene analysis by exon-specific sequencing revealed no abnormality in all three patients. These results indicate that the presence of IgG anti-FH antibodies led to an acquired functional FH deficiency. As reported among hereditary FH-deficient individuals (4,22,23), two of three patients presented with low C3 levels, suggestive of mild alternative pathway-mediated complement activation.

The effect of the anti-FH antibodies on the capacity that the FH have to control activation of the complement system was estimated using three different assays: Analysis of the decay-accelerating activity of the alternative pathway C3 convertase, analysis of the binding of FH to surface-bound C3b, and analysis of the co-factor activity of FH in the proteolysis of fluid-phase C3b by factor I. The results showed perturbation of decay-accelerating activity in the three patients. This perturbation was in correlation with the anti-FH antibody titers for patients 1 and 2. No inhibition by purified IgG-containing anti-FH antibodies of the FH capacity to bind surface-bound C3b was observed under our experimental conditions. As three distinct binding sites to C3b have been identified in FH, maybe a perturbation of one of the binding sites could not be detected by this assay. Co-factor activity of purified FH was not modified by an incubation with purified IgG-containing anti-FH antibodies. This result suggests that the epitopes recognized by the autoantibodies are not implicated in this function, which has been shown to be related to SCR1 to 4 (24). This is in agreement with our results demonstrating no inhibition of the binding of the anti-FH antibodies to immobilized FH by a mouse monoclonal anti-FH antibody specific for a region that comprises SCR1 to 4.

We suggest that these autoantibodies probably influence the binding of FH to the C3b,Bb convertase, thereby compromising FH activity in vivo. This is not the first example of autoantibodies that do not neutralize the antigen activity. An example of nonneutralizing anti–ADAMST-13 antibodies was recently reported in a patient who had TTP and severely reduced ADAMST-13 activity but showed no ADAMST-13 inhibition in a fluid-phase activity assay (25). Epitope mapping of the anti-FH antibodies will be important for the understanding of the mechanisms of this FH inhibition in vivo.

Similar to the reported patients who carry an FH gene mutation (5–9), the clinical features of the three patients were recurrent HUS leading to end-stage renal failure at the second relapse in patient 1. A recurrent form of HUS is an essential criterion for an atypical form of HUS. Two of the three patients exhibited an episode of diarrhea. The presence of diarrhea is the main clinical criterion used for the classification between typical and atypical HUS, but it may be absent in a confirmed Stx-related HUS (26) and present in the other forms, as a result of microangiopathic lesions of the gut (21,23,27,28). For that reason, it may be preferable to use the term Stx-HUS rather than postdiarrheal HUS.

It is worth noting that all three patients exhibited ANA that may be related to this particular form of disease. A recent study reporting on 81 adult thrombotic microangiopathies revealed that ANA were highly frequent in idiopathic TMA (41.3%) and were frequently associated with an acquired ADAMST-13 deficiency (29). The association of ANA with organ-specific autoantibodies is frequently reported in various autoimmune disorders, such as myasthenia gravis and autoimmune thyroiditis (30,31), pointing to the importance of immune dysregulation in the induction of these autoimmune diseases. None of the three patients had presented before and since the onset of HUS any symptom and any other biologic marker of systemic autoimmune disease such as systemic lupus erythematosus.

Although beneficial effect of plasma exchanges is unproved in atypical HUS in contrast to TTP (1,32), this therapy has been effective in two patients, maybe because of the removal of the anti-FH antibodies. Both patients remain without recurrence with an immunosuppressive treatment using azathioprine in one case and glucocorticoids in the other. The identification of anti-FH antibodies may lead to the design of new approaches of diagnosis and treatment with a particular interest in plasma exchanges or immunosuppressive therapies.

Similar to the observations of acquired von Willebrand factor–cleaving protease deficiencies secondary to IgG antibodies in patients who exhibit TTP, our report provides evidence for the first time that HUS may occur in a context of an autoimmune disease with the development of anti–FH-specific antibodies leading to an acquired FH deficiency. This new mechanism of functional FH deficiency emphasizes the role of the alternative pathway regulatory function of FH in the process of the illness.


   Acknowledgment
 
This work was supported in part by the Institut National de la Santé et de la Recherche Médicale (INSERM).


   Footnotes
 
Published online ahead of print. Publication date available at www.jasn.org.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Moake JL: Thrombotic microangiopathies. N Engl J Med 347 : 589 –600, 2002[Free Full Text]
  2. Ripoche J, Day AJ, Harris TJ, Sim RB: The complete amino acid sequence of human complement factor H. Biochem J 249 : 593 –602, 1988[Medline]
  3. DiScipio RG: Ultrastructures and interactions of complement factors H and I. J Immunol 149 : 2592 –2599, 1992[Abstract]
  4. Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, Coppo P, Fridman WH, Weiss L: Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: Report and genetic analysis of 16 cases. J Am Soc Nephrol 15 : 787 –795, 2004[Abstract/Free Full Text]
  5. Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, Turnpenny P, Goodship JA: Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 53 : 836 –844, 1998[CrossRef][Medline]
  6. Perez-Caballero D, Gonzalez-Rubio C, Gallardo ME, Vera M, Lopez-Trascasa M, Rodriguez de Cordoba S, Sanchez-Corral P: Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 68 : 478 –484, 2001[CrossRef][Medline]
  7. Richards A, Buddles MR, Donne RL, Kaplan BS, Kirk E, Venning MC, Tielemans CL, Goodship JA, Goodship TH: Factor H mutations in hemolytic uremic syndrome cluster in exons 18–20, a domain important for host cell recognition. Am J Hum Genet 68 : 485 –490, 2001[CrossRef][Medline]
  8. Caprioli J, Bettinaglio P, Zipfel PF, Amadei B, Daina E, Gamba S, Skerka C, Marziliano N, Remuzzi G, Noris M: The molecular basis of familial hemolytic uremic syndrome: Mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 12 : 297 –307, 2001[Abstract/Free Full Text]
  9. Neumann HP, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D, Bender BU, Cybulla M, Riegler P, Konigsrainer A, Neyer U, Bock A, Widmer U, Male DA, Franke G, Zipfel PF: Haemolytic uraemic syndrome and mutations of the factor H gene: A registry-based study of German speaking countries. J Med Genet 40 : 676 –681, 2003[Abstract/Free Full Text]
  10. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Muslumanoglu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship TH: Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 100 : 12966 –12971, 2003[Abstract/Free Full Text]
  11. Noris M, Brioschi S, Caprioli J, Todeschini M, Bresin E, Porrati F, Gamba S, Remuzzi G: Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362 : 1542 –1547, 2003[CrossRef][Medline]
  12. Tsai HM, Lian EC: Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339 : 1585 –1594, 1998[Abstract/Free Full Text]
  13. Furlan M, Robles R, Solenthaler M, Lammle B: Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 91 : 2839 –2846, 1998[Abstract/Free Full Text]
  14. Furlan M, Lammle B: Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. Baillieres Clin Haematol 11 : 509 –514, 1998[CrossRef][Medline]
  15. Tsai HM: Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost 1 : 625 –631, 2003[CrossRef][Medline]
  16. Horton TM, Stone JD, Yee D, Dreyer Z, Moake JL, Mahoney DH: Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol 25 : 336 –339, 2003[CrossRef][Medline]
  17. Kazatchkine MD, Hauptmann G, Nydegger U: Techniques de Complément, Paris, Société Française d’Immunologie, 1985
  18. Kazatchkine MD, Fearon DT, Austen KF: Human alternative complement pathway: Membrane-associated sialic acid regulates the competition between B and {beta}1 H for cell-bound C3b. J Immunol 122 : 75 –81, 1979[Abstract/Free Full Text]
  19. Jeanpierre M: A rapid method for the purification of DNA from blood. Nucleic Acids Res 15 : 9611 , 1987[Free Full Text]
  20. Jokiranta TS, Solomon A, Pangburn MK, Zipfel PF, Meri S: Nephritogenic lambda light chain dimer: A unique human miniautoantibody against complement factor H. J Immunol 163 : 4590 –4596, 1999[Abstract/Free Full Text]
  21. Pichette V, Querin S, Schurch W, Brun G, Lehner-Netsch G, Delage JM: Familial hemolytic-uremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 24 : 936 –941, 1994[Medline]
  22. Ault BH: Factor H and the pathogenesis of renal diseases. Pediatr Nephrol 14 : 1045 –1053, 2000[CrossRef][Medline]
  23. Rougier N, Kazatchkine MD, Rougier JP, Fremeaux-Bacchi V, Blouin J, Deschenes G, Soto B, Baudouin V, Pautard B, Proesmans W, Weiss E, Weiss L: Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 9 : 2318 –2326, 1998[Abstract]
  24. Kuhn S, Skerka C, Zipfel PF: Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1. J Immunol 155 : 5663 –5670, 1995[Abstract]
  25. Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal M, Dorner F, Rieger M: Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 102 : 3241 –3243, 2003[Abstract/Free Full Text]
  26. Caprioli A, Pezzella C, Morelli R, Giammanco A, Arista S, Crotti D, Facchini M, Guglielmetti P, Piersimoni C, Luzzi I: Enteropathogens associated with childhood diarrhea in Italy. The Italian Study Group on Gastrointestinal Infections. Pediatr Infect Dis J 15 : 876 –883, 1996[CrossRef][Medline]
  27. Bogdanovic R, Cvoric A, Nikolic V, Sindjic M: Recurrent haemolytic-uraemic syndrome with hypocomplementaemia: a case report. Pediatr Nephrol 2 : 236 –238, 1988[CrossRef][Medline]
  28. Petermann A, Offermann G, Distler A, Sharma AM: Familial hemolytic-uremic syndrome in three generations. Am J Kidney Dis 32 : 1063 –1067, 1998[Medline]
  29. Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, Malot S, Heshmati F, Mira JP, Boulanger E, Galicier L, Durey-Dragon MA, Fremeaux-Bacchi V, Ramakers M, Pruna A, Bordessoule D, Gouilleux V, Scrobohaci ML, Vernant JP, Moreau D, Azoulay E, Schlemmer B, Guillevin L, Lassoued K: Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 83 : 233 –244, 2004[Medline]
  30. Barbosa RE, Cordova S, Cajigas JC: Coexistence of systemic lupus erythematosus and myasthenia gravis. Lupus 9 : 156 –157, 2000[Free Full Text]
  31. Morita S, Arima T, Matsuda M: Prevalence of nonthyroid specific autoantibodies in autoimmune thyroid diseases. J Clin Endocrinol Metab 80 : 1203 –1206, 1995[Abstract]
  32. Allford SL, Hunt BJ, Rose P, Machin SJ: Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 120 : 556 –573, 2003[CrossRef][Medline]
Received for publication May 12, 2004. Accepted for publication October 22, 2004.


Related Article

This Month’s Highlights
J. Am. Soc. Nephrol. 2005 16: 279-283. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 BloodHome page
F. Fakhouri, M. Jablonski, J. Lepercq, J. Blouin, A. Benachi, M. Hourmant, Y. Pirson, A. Durrbach, J.-P. Grunfeld, B. Knebelmann, et al.
Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome
Blood, December 1, 2008; 112(12): 4542 - 4545.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
T. Kwon, M.-A. Dragon-Durey, M.-A. Macher, V. Baudouin, A. Maisin, M. Peuchmaur, V. Fremeaux-Bacchi, and C. Loirat
Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 2088 - 2090.
[Full Text] [PDF]

Home page
 BloodHome page
A.-l. Stahl, F. Vaziri-Sani, S. Heinen, A.-C. Kristoffersson, K.-H. Gydell, R. Raafat, A. Gutierrez, O. Beringer, P. F. Zipfel, and D. Karpman
Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation
Blood, June 1, 2008; 111(11): 5307 - 5315.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. Martinez-Barricarte, G. Pianetti, R. Gautard, J. Misselwitz, L. Strain, V. Fremeaux-Bacchi, C. Skerka, P. F. Zipfel, T. Goodship, M. Noris, et al.
The Complement Factor H R1210C Mutation Is Associated With Atypical Hemolytic Uremic Syndrome
J. Am. Soc. Nephrol., March 1, 2008; 19(3): 639 - 646.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Jozsi, C. Licht, S. Strobel, S. L. H. Zipfel, H. Richter, S. Heinen, P. F. Zipfel, and C. Skerka
Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency
Blood, February 1, 2008; 111(3): 1512 - 1514.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. M. Markiewski and J. D. Lambris
The Role of Complement in Inflammatory Diseases From Behind the Scenes into the Spotlight
Am. J. Pathol., September 1, 2007; 171(3): 715 - 727.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Jozsi, S. Strobel, H.-M. Dahse, W.-s. Liu, P. F. Hoyer, M. Oppermann, C. Skerka, and P. F. Zipfel
Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome
Blood, September 1, 2007; 110(5): 1516 - 1518.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A.-L. Sellier-Leclerc, V. Fremeaux-Bacchi, M.-A. Dragon-Durey, M.-A. Macher, P. Niaudet, G. Guest, B. Boudailliez, F. Bouissou, G. Deschenes, S. Gie, et al.
Differential Impact of Complement Mutations on Clinical Characteristics in Atypical Hemolytic Uremic Syndrome
J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2392 - 2400.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
D. Kavanagh, A. Richards, V. Fremeaux-Bacchi, M. Noris, T. Goodship, G. Remuzzi, and J. P. Atkinson
Screening for Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome
Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 591 - 596.
[Full Text] [PDF]

Home page
 J. Med. Genet.Home page
A. Servais, V. Fremeaux-Bacchi, M. Lequintrec, R. Salomon, J. Blouin, B. Knebelmann, J.-P. Grunfeld, P. Lesavre, L.-H. Noel, and F. Fakhouri
Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome
J. Med. Genet., March 1, 2007; 44(3): 193 - 199.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. Heinen, M. Jozsi, A. Hartmann, M. Noris, G. Remuzzi, C. Skerka, and P. F. Zipfel
Hemolytic Uremic Syndrome: A Factor H Mutation (E1172Stop) Causes Defective Complement Control at the Surface of Endothelial Cells
J. Am. Soc. Nephrol., February 1, 2007; 18(2): 506 - 514.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
D. Kavanagh, T. H. J. Goodship, and A. Richards
Atypical haemolytic uraemic syndrome
Br. Med. Bull., October 5, 2006; (2006) ldl004v2.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Caprioli, M. Noris, S. Brioschi, G. Pianetti, F. Castelletti, P. Bettinaglio, C. Mele, E. Bresin, L. Cassis, S. Gamba, et al.
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome
Blood, August 15, 2006; 108(4): 1267 - 1279.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
V. Fremeaux-Bacchi, E. A. Moulton, D. Kavanagh, M.-A. Dragon-Durey, J. Blouin, A. Caudy, N. Arzouk, R. Cleper, M. Francois, G. Guest, et al.
Genetic and Functional Analyses of Membrane Cofactor Protein (CD46) Mutations in Atypical Hemolytic Uremic Syndrome
J. Am. Soc. Nephrol., July 1, 2006; 17(7): 2017 - 2025.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. M. Thurman and V. M. Holers
The Central Role of the Alternative Complement Pathway in Human Disease
J. Immunol., February 1, 2006; 176(3): 1305 - 1310.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
E. Bresin, E. Daina, M. Noris, F. Castelletti, R. Stefanov, P. Hill, T. H.J. Goodship, G. Remuzzi, and for the International Registry of Recurrent and Fa
Outcome of Renal Transplantation in Patients with Non-Shiga Toxin-Associated Hemolytic Uremic Syndrome: Prognostic Significance of Genetic Background
Clin. J. Am. Soc. Nephrol., January 1, 2006; 1(1): 88 - 99.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Jozsi, S. Heinen, A. Hartmann, C. W. Ostrowicz, S. Halbich, H. Richter, A. Kunert, C. Licht, R. E. Saunders, S. J. Perkins, et al.
Factor H and Atypical Hemolytic Uremic Syndrome: Mutations in the C-Terminus Cause Structural Changes and Defective Recognition Functions
J. Am. Soc. Nephrol., January 1, 2006; 17(1): 170 - 177.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Noris and G. Remuzzi
Hemolytic Uremic Syndrome
J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1035 - 1050.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2004050380v1
16/2/555    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dragon-Durey, M.-A.
Right arrow Articles by Frémeaux-Bacchi, V.
Right arrow Search for Related Content
PubMed
Right arrow